Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Cushion insole OEM solution Vietnam

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Arch support insole OEM from Taiwan

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Taiwan custom neck pillow ODM

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Innovative insole ODM solutions factory in Taiwan

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Taiwan flexible graphene product manufacturing

Poor gut health may worsen COVID-19 prognosis. This could occur by allowing the virus access to the digestive tract and internal organs, which are vulnerable due to the presence of ACE2 protein. COVID-19 severity may be tied to gut microbiome imbalances, especially in people with chronic illness or fiber-poor diets. Severe cases of COVID-19 often include GI symptoms Chronic diseases associated with severe COVID-19 are also associated with altered gut microbiota A growing body of evidence suggests poor gut health adversely affects prognosis If studies do empirically demonstrate a connection between the gut microbiota and COVID-19 severity, then interventions like probiotics or fecal transplants may help patients People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems. However, autopsy and other studies have also revealed that the infection can affect the liver, kidney, heart, spleen — and even the gastrointestinal tract. A sizeable fraction of patients hospitalized with breathing problems also have diarrhea, nausea and vomiting, suggesting that when the virus does get involved in the GI tract it increases the severity of the disease. Leaky Gut May Worsen Viral Spread In a review published this week in the journal mBio, microbiologist Heenam Stanley Kim, Ph.D, from Korea University’s Laboratory for Human-Microbial Interactions, in Seoul, examined emerging evidence suggesting that poor gut health adversely affects COVID-19 prognosis. Based on his analysis, Kim proposed that gut dysfunction — and its associated leaky gut — may exacerbate the severity of infection by enabling the virus to access the surface of the digestive tract and internal organs. These organs are vulnerable to infection because they have widespread ACE2 — a protein target of SARS-CoV-2 — on the surface. “There seems to be a clear connection between the altered gut microbiome and severe COVID-19,” Kim said. The virus that causes COVID-19, called SARS-CoV-2, shown here in an electron microscope image. Credit: NIAID-RML Studies have demonstrated that people with underlying medical conditions including high blood pressure, diabetes and obesity face a higher risk of severe COVID-19. Risk also increases with age, with older adults most vulnerable to the most serious complications and likelihood of hospitalization. But both of these factors — advanced age and chronic conditions — have a well-known association with an altered gut microbiota. This imbalance can affect gut barrier integrity, Kim noted, which can allow pathogens and pathobionts easier access to cells in the intestinal lining. So far, the link between gut health and COVID-19 prognosis hasn’t been empirically demonstrated, Kim noted. Some researchers have argued, he said, that unhealthy gut microbiomes may be an underlying reason for why some people have such severe infections. What studies have been done hint at a complicated relationship. A study on symptomatic COVID-19 patients in Singapore, for example, found that about half had a detectable level of the coronavirus in fecal tests — but only about half of those experienced GI symptoms. That study suggests that even if SARS-CoV-2 reaches the GI tract, it may not cause problems. Kim also noted that a person’s gut health at the time of infection may be critical for symptom development. Microbiome Shifts Detected in COVID-19 Patients Many recent studies have found reduced bacterial diversity in gut samples collected from COVID-19 patients, compared to samples from healthy people. The disease has also been linked to a depletion of beneficial bacterial species — and the enrichment of pathogenic ones. A similar imbalance has been associated with influenza A infection, though the 2 viruses differ in how they change the overall microbial composition. The depleted bacterial species associated with COVID-19 infection include some families that are responsible for producing butyrate, a short-chain fatty acid, which plays a pivotal role in gut health by reinforcing gut-barrier function. Kim said he started analyzing the studies after realizing that wealthy countries with a good medical infrastructure — including the United States and nations in Western Europe — were among the hardest hit by the virus. The “western diet” that’s common in these countries is low in fiber, and “a fiber-deficient diet is one of the main causes of altered gut microbiomes,” he said, “and such gut microbiome dysbiosis leads to chronic diseases.” Fiber and Microbiome Restoration as Future Therapies The pathogenesis of COVID-19 is still not fully understood. If future studies do show that gut health affects COVID-19 prognosis, Kim argued, then clinicians and researchers should exploit that connection for better strategies aimed at preventing and managing the disease. Eating more fiber, he said, may lower a person’s risk of serious disease. And fecal microbiota transplantation might be a treatment worth considering for patients with the worst cases of COVID-19. The problem with gut health goes beyond COVID-19, though, he said. Once the pandemic passes, the world will still have to reckon with chronic diseases and other problems associated with poor gut health. “The whole world is suffering from this COVID-19 pandemic,” Kim said, “but what people do not realize is that the pandemic of damaged gut microbiomes is far more serious now.” Reference: “Do an Altered Gut Microbiota and an Associated Leaky Gut Affect COVID-19 Severity?” by Heenam Stanley Kim, 12 January 2021, mBio. DOI: 10.1128/mBio.03022-20 The American Society for Microbiology is one of the largest professional societies dedicated to the life sciences and is composed of 30,000 scientists and health practitioners. ASM’s mission is to promote and advance the microbial sciences. ASM advances the microbial sciences through conferences, publications, certifications and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences.

Müller glia (green) and their progeny (red) regenerate nerve cells and photoreceptors in a mouse retina. Credit: Ksenia Gnedeva/USC A USC research team discovered that a single genetic signal may be preventing both hearing and vision cells from repairing themselves. By turning off this signal in mice, they triggered cell growth in parts of the ear and eye — a step toward possible future therapies for hearing and vision loss. A new mouse study from the USC Stem Cell lab of Ksenia Gnedeva, PhD, suggests that the same genes may control the regeneration of sensory cells in both the ear and the eye. The research, published today (March 31) in Proceedings of the National Academy of Sciences (PNAS), offers insight into why these cells fail to regenerate in mammals, and how that barrier might be lifted. Unlocking Regeneration in Ear and Eye “The proliferation of progenitor cells in response to injury is a crucial step in the regeneration of sensory receptors, but this process is blocked in the mammalian inner ear and retina. By understanding the genes that enforce this block, we can advance efforts to restore hearing and vision in patients,” said Gnedeva, an assistant professor in the USC Tina and Rick Caruso Department of Otolaryngology – Head and Neck Surgery, and the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC. The Hippo Pathway: A Cellular Stop Signal The team, led by first authors Eva Jahanshir and Juan Llamas, focused on a network of genes known as the Hippo pathway. This pathway acts as a “stop growing” signal, previously shown by the lab to limit cell proliferation in the developing ear. In this study, the researchers found that the same pathway also suppresses the regrowth of damaged sensory cells in the ears and eyes of adult mice. To test whether they could overcome this barrier, the scientists used a compound developed in their lab that inhibits a key Hippo pathway protein, Lats1/2. When inner ear progenitor cells, known as supporting cells, were exposed to this compound in a Petri dish, they began to multiply in the utricle, a balance-sensing organ. However, the same effect was not observed in the organ of Corti, which is responsible for hearing. The Role of p27Kip1 in Blocking Regeneration The scientists next identified what was blocking this important step towards sensory cell regeneration in the organ of Corti — a gene encoding a protein called p27Kip1 — and showed that this inhibitory protein was also high in the retina. They created a transgenic mouse in which the level of p27Kip1 could be reduced in the inner ear and the retina to see how that would impact the proliferation of progenitor cells in response in both organs. In these mice, inhibiting the Hippo pathway effectively caused supporting cells proliferation in the organ of Corti, an important step towards the regeneration of the ear’s sensory cells. In the retina, inhibiting the Hippo pathway induced the proliferation of progenitor cells known as Müller glia. Surprisingly, the researchers discovered that some of the Müller glia progeny, without further manipulation, converted to sensory photoreceptors and other neuronal cell types in the retina. A Window of Regenerative Opportunity “There have been reports that p27Kip1 levels drop following injury, so that might offer a brief window of opportunity for using a drug-like compound to inhibit the Hippo pathway and encourage regeneration in the ear and the eye,” said Gnedeva. “Alternatively, it could be possible to develop another drug-like compound to reduce p27Kip1 levels. So, our discoveries have identified potential new targets for stimulating the regeneration of both hearing and vision.” Reference: “The Hippo pathway and p27Kip1 cooperate to suppress mitotic regeneration in the organ of Corti and the retina” by Eva Jahanshir, Juan Llamas, Yeeun Kim, Kevin Biju, Sanyukta Oak and Ksenia Gnedeva, 3 April 2025, Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2411313122 Additional co-authors are Yeeun Kim, Kevin Biju, and Sanyukta Oak from the Gnedeva Lab. This work was supported by federal funding from the National Institutes of Health’s National Institute on Deafness and Other Communication Disorders (grant 1R01DC020268, training grant T32DC009975, and clinician-scientist training grant 5R25DC019700). Disclosures Gnedeva is a co-inventor on three patent applications related to this work: 1. Lats kinase inhibitor to treat retinal degeneration (PCT application number PCT/US2024/023146; U.S. Patent and Trademark serial number usc0282prv); 2. Pyrrolopyridine-3- and 4-carboxamide compositions and methods for cellular proliferation (docket number 2877.035P1); and 3. Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss (application number 62970425).

Research from the Garvan Institute of Medical Research indicates that non-coding DNA, which comprises 98% of our genome and was previously considered “junk,” may play a crucial role in cancer diagnosis and treatment. The study found mutations in these regions that are linked to 12 different cancer types. These mutations occur in binding sites for the CTCF protein, which are vital for maintaining the genome’s 3D structure. Disruptions in these sites may contribute to cancer development. The findings suggest a potential universal approach to cancer treatment that targets these common mutations across various cancers. Researchers at the Garvan Institute have utilized artificial intelligence to identify potential cancer-causing elements within the ‘junk’ regions of DNA, paving the way for innovative methods in diagnosis and treatment. According to a new study from the Garvan Institute of Medical Research, non-coding DNA—which makes up 98% of our genome and does not contain instructions for making proteins—may hold the key to new cancer diagnostics and treatments. The findings, published in the journal Nucleic Acids Research, reveal mutations in previously overlooked regions of the genome that may contribute to the formation and progression of at least 12 different cancers, including prostate, breast, and colorectal cancer. The discovery could lead to early diagnosis and new treatments effective for many cancer types. “Non-coding DNA was once dismissed as ‘junk DNA’ due to its apparent lack of function,” says Dr Amanda Khoury, Research Officer at Garvan and co-corresponding author of the study. “Our research has found mutations in these DNA regions that could open an entirely new, universal approach to cancer treatment.” Visualized DNA damage (green) in human breast cancer cells (blue). Credit: Garvan Institute Investigating DNA ‘anchors’ disrupted in cancer The researchers focused on mutations affecting binding sites for a protein called CTCF, which helps fold long strands of DNA into specific shapes. In their previous work, they found that these binding sites bring distant parts of the DNA close together, forming 3D structures that control which genes are turned on or off. “We had already identified a subset of CTCF binding sites that are ‘persistent’ – that is they act like anchors in the genome, present across different cell types,” says Dr Khoury. “We hypothesized that if these anchors become faulty, it could disrupt the normal 3D organization of the genome and contribute to cancer.” To test this, the researchers developed a new sophisticated machine learning (AI) tool called CTCF-INSITE, which used genomic and epigenomic features to predict which CTCF sites are likely to be persistent anchors in a total of 12 cancer types. They then assessed more than 3000 tumor samples from patients diagnosed with the 12 cancer types, available from the International Genome Consortium database, and found the persistent anchors were rich with mutations. Dr Amanda Khoury and Professor Susan Clark at the Garvan Institute of Medical Research in Sydney, Australia. Credit: Garvan Institute “Using our machine learning tool, we identified persistent CTCF binding sites in 12 different cancer types,” says Dr Wenhan Chen, first author of the study. “Remarkably, we found that every cancer sample had at least one mutation in a persistent CTCF binding site.” “This research confirmed that persistent CTCF binding sites are ‘mutational hotspots’ in cancers. We think these mutations give cancer cells a survival advantage, allowing them to proliferate and spread,” adds Dr Khoury. Toward a universal cancer treatment approach The findings could have broad implications for understanding and treating many types of cancer. “Most new cancer treatments have to be carefully targeted to specific mutations not always common amongst different tumor types, but because these CTCF anchors are mutated across multiple different cancer types, we’re opening up the possibility of developing approaches that could be effective for multiple cancers,” says Professor Susan Clark, Head of the Cancer Epigenetics Lab at Garvan and lead author of the study. The researchers are now planning further large-scale experiments using CRISPR gene editing to investigate how these anchor mutations disrupt the 3D genome and potentially promote cancer growth. “Now that we’ve discovered what we believe to be critical anchors of the genome and shown they are important to maintaining homeostasis of the genome architecture, it makes sense that these non-coding DNA mutations would disrupt this homeostasis in the cancer cell – a hypothesis we will test when we edit them out,” says Professor Clark. “Observing the downstream impact, we hope to identify key genes or gene pathways that are affected by the mutations, which could serve as markers for early cancer detection or targets for new treatments.” “Finding these clues that were hidden in a vast amount of data is a powerful example of how artificial intelligence is boosting medical research,” she says. “This is a whole new frontier in the study of cancer, and we’re excited to explore it further.” Reference: “Machine learning enables pan-cancer identification of mutational hotspots at persistent CTCF binding sites” by Wenhan Chen, Yi C Zeng, Joanna Achinger-Kawecka, Elyssa Campbell, Alicia K Jones, Alastair G Stewart, Amanda Khoury and Susan J Clark, 2 July 2024, Nucleic Acids Research. DOI: 10.1093/nar/gkae530 This research was supported by a National Health and Medical Research Council Ideas grant and Investigator grant funding.

DVDV1551RTWW78V